"In my experience, the Acuity Steerable lead with the use of the stylet has enabled me to place the lead where I want to have it even in very difficult anatomies", stated Dr. Martin Desaga, Amper Kliniken Dachau, near Munich, Germany.
Since Guidant introduced bipolar left ventricular leads in Europe in 2002, physicians have rapidly and overwhelmingly adopted this technology. Approximately 90 percent of procedures involving a cardiac resynchronization therapy product from Guidant's Renewal family of devices now also include bipolar leads.
"Guidant has a track record of recognizing the needs of physicians and the patients that they serve", stated Fred McCoy, president, Cardiac Rhythm Management, Guidant Corporation. "This important addition to our heart failure lead family underscores our commitment to meaningful innovation."
"Delivery of the LV lead where you prescribe it, and not where you can get it, is one of the most critical aspects of any cardiac resynchronization therapy system implant", stated Dr. Stephen Mester, Tampa General Hospital, Tampa, Florida, who served as principal investigator for the Acuity Steerable clinical trial.
Guidant expects to launch the Acuity Steerable lead in the United States in 2006, pending Food and Drug Administration approval.
Guidant Corporation pioneers lifesaving technology, giving an opportunity for better life today to millions of cardiac and vascular patients worldwide. The company develops, manufactures and markets a broad array of products and services that enable less invasive care for some of life's most threatening medical conditions. More company news is available in the VMW December 2003 article Guidant broadens Advanced Patient Management initiative with CardioMEMS investment.